ANI Pharma (ANIP) Tops Q1 EPS by 60c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $2.05, $0.60 better than the analyst estimate of $1.45. Revenue for the quarter came in at $237.5 million versus the consensus estimate of $213.42 million.

GUIDANCE:

ANI Pharma sees FY2026 EPS of $9.19-$9.69, versus the consensus of $9.07. ANI Pharma sees FY2026 revenue of $1.08-1.14 billion, versus the consensus of $1.09 billion.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• XORTX to voluntarily delist from TSX Venture Exchange
• PreveCeutical closes second tranche of private placement for $245,000